TandemAI and Mila Partner to Pioneer 'World Models' for AI-Driven Drug Discovery

(New York and Montreal, May 19, 2026) TandemAI and Mila (Quebec Artificial Intelligence Institute) recently announced a research partnership to jointly promote the deep application of AI-driven drug discovery and explore the potential of cutting-edge "world model" technology in the field of molecular science.

This collaboration will fully leverage TandemAI's technical advantages in AI-driven drug discovery platforms and Mila's academic accumulation in fundamental AI research. Both parties will focus on accelerating the development of safe and effective therapies by integrating generative artificial intelligence, physics-based computational modeling, and experimental validation, jointly addressing major challenges in human health.

The long-term vision of the collaboration focuses on exploring the application of "world models" in drug discovery. As a general machine learning framework designed to understand and simulate the operating principles of the physical world, "world models" have demonstrated tremendous potential in fields such as autonomous driving and robotics. However, their application in molecular science and drug development remains at the cutting-edge frontier. TandemAI and Mila plan to jointly develop new models capable of more accurately representing chemical and atomic-level physical systems, with the goal of empowering researchers to conduct virtual experiments with broader scope and higher precision, thereby significantly improving laboratory efficiency and shortening the new drug development cycle.

This collaboration also reflects the shared commitment of both parties to open science and responsible AI development. TandemAI and Mila firmly believe that advancing in this field requires transparency and cooperation with the broader scientific community, and both will actively promote the open exchange of relevant knowledge in line with their respective values.

TandemAI Chief Technology Officer Albert PanSaid: "Since its inception, TandemAI has firmly believed that the integration of cutting-edge AI and physics-based modeling technologies will play a pivotal role in shaping the future of drug discovery. Collaborating with Mila, a leading institution in deep learning research, is a natural and exciting step forward. We look forward to jointly exploring new pathways for applying AI in drug development—such as creating 'world models' that better capture the underlying principles of chemistry and physics—and striving to gradually translate these technological advancements into superior drugs that benefit patients."

Mila Executive Vice President Stéphane LétourneauSaid: "At Mila, we focus on AI research that connects to real-world challenges. Drug discovery is precisely where machine learning can have a substantial and lasting impact on human health. We are excited to collaborate with TandemAI, whose integrated platform will provide an ideal environment for Mila researchers to help translate fundamental AI research into meaningful outcomes."

Analysts believe that artificial intelligence is profoundly transforming the traditional drug research and development model. The deep integration of AI and drug discovery is expected to significantly shorten the R&D cycle and reduce failure risks. This strong collaboration between TandemAI and Mila will inject new technological momentum into global new drug R&D, help solve pharmaceutical innovation challenges, and benefit more patients.

TandemAI is a globally leading AI-native innovative drug discovery platform and a biotechnology company that achieves a commercial closed loop, with operations spanning various drug modalities such as small molecules, peptides, and peptide-conjugated drugs. The company leverages its self-developed world model and autonomously evolving all-weather AI scientist agents as the dual technological cores to construct a closed-loop evolutionary system of "data-driven models, model-guided experiments, and experiment-refined models." This enables an end-to-end intelligent workflow from target validation to the identification of preclinical candidate compounds (PCC), significantly enhancing the efficiency and success rate of high-quality molecule drug discovery.

TandemAI has cumulatively established partnerships with over 200 pharmaceutical companies and research institutions worldwide, covering four of the top ten global firms and multiple top twenty multinational pharmaceutical enterprises. It has over 50 collaborative and self-developed pipelines, with several projects already entering the clinical development stage. The company is supported by top-tier institutions such as Orbimed, Qiming Venture Partners, Sequoia Capital, and Chengwei Capital. TandemAI has been featured in Nature Index's global AI-driven drug discovery landscape, ranked among Forbes Asia’s Top 100 notable companies, and formed strategic collaborations with world-leading deep learning research institutes like Mila.

The Quebec Artificial Intelligence Institute (Mila), founded by Professor Yoshua Bengio, is the world's largest academic artificial intelligence research center focused on deep learning, with over 1,500 researchers. Headquartered in Montreal, Mila originated from a unique partnership between the Université de Montréal and McGill University. It is dedicated to driving scientific breakthroughs that spark innovation and ensuring that artificial intelligence benefits everyone. As a non-profit organization, Mila receives strong support from the Canadian government through the Pan-Canadian AI Strategy and from the Quebec provincial government. Renowned internationally for its impactful research, global innovative partnerships, and leadership in multilateral efforts for responsible AI, Mila continues to shape the future of global AI.